Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multicenter, International, Open-Label Study of Infliximab Plus Methotrexate Versus Methotrexate (MTX) Alone for the Treatment of MT naïve Subjects With Active Psoriatic Arthritis.

Next Previous
X
Search
Trial Profile

A Randomized, Multicenter, International, Open-Label Study of Infliximab Plus Methotrexate Versus Methotrexate (MTX) Alone for the Treatment of MT naïve Subjects With Active Psoriatic Arthritis.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Infliximab (Primary) ; Methotrexate
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Acronyms RESPOND
  • Sponsors Integrated Therapeutics Group; Merck Sharp & Dohme; Schering-Plough

    • Most Recent Events

    • 15 Jun 2019 This trial has been completed in Slovakia, according to European Clinical Trials Database.
    • 12 Oct 2011 Results published in full in the Annals of the Rheumatic Diseases.
    • 21 Oct 2009 Results presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top